162 related articles for article (PubMed ID: 12900760)
1. A strict-late viral promoter is a strong tumor-specific promoter in the context of an oncolytic herpes simplex virus.
Fu X; Meng F; Tao L; Jin A; Zhang X
Gene Ther; 2003 Aug; 10(17):1458-64. PubMed ID: 12900760
[TBL] [Abstract][Full Text] [Related]
2. Development of a second-generation oncolytic Herpes simplex virus expressing TNFalpha for cancer therapy.
Han ZQ; Assenberg M; Liu BL; Wang YB; Simpson G; Thomas S; Coffin RS
J Gene Med; 2007 Feb; 9(2):99-106. PubMed ID: 17256802
[TBL] [Abstract][Full Text] [Related]
3. Effective treatment of tumors with strong beta-catenin/T-cell factor activity by transcriptionally targeted oncolytic herpes simplex virus vector.
Kuroda T; Rabkin SD; Martuza RL
Cancer Res; 2006 Oct; 66(20):10127-35. PubMed ID: 17047077
[TBL] [Abstract][Full Text] [Related]
4. Hepatoma-specific antitumor activity of an albumin enhancer/promoter regulated herpes simplex virus in vivo.
Miyatake SI; Tani S; Feigenbaum F; Sundaresan P; Toda H; Narumi O; Kikuchi H; Hashimoto N; Hangai M; Martuza RL; Rabkin SD
Gene Ther; 1999 Apr; 6(4):564-72. PubMed ID: 10476216
[TBL] [Abstract][Full Text] [Related]
5. Identification of the transcriptional regulatory sequences of human calponin promoter and their use in targeting a conditionally replicating herpes vector to malignant human soft tissue and bone tumors.
Yamamura H; Hashio M; Noguchi M; Sugenoya Y; Osakada M; Hirano N; Sasaki Y; Yoden T; Awata N; Araki N; Tatsuta M; Miyatake SI; Takahashi K
Cancer Res; 2001 May; 61(10):3969-77. PubMed ID: 11358814
[TBL] [Abstract][Full Text] [Related]
6. Potent systemic antitumor activity from an oncolytic herpes simplex virus of syncytial phenotype.
Fu X; Zhang X
Cancer Res; 2002 Apr; 62(8):2306-12. PubMed ID: 11956088
[TBL] [Abstract][Full Text] [Related]
7. Ionizing radiation activates late herpes simplex virus 1 promoters via the p38 pathway in tumors treated with oncolytic viruses.
Mezhir JJ; Advani SJ; Smith KD; Darga TE; Poon AP; Schmidt H; Posner MC; Roizman B; Weichselbaum RR
Cancer Res; 2005 Oct; 65(20):9479-84. PubMed ID: 16230412
[TBL] [Abstract][Full Text] [Related]
8. Herpes simplex virus Us3(-) mutant as oncolytic strategy and synergizes with phosphatidylinositol 3-kinase-Akt targeting molecular therapeutics.
Liu TC; Wakimoto H; Martuza RL; Rabkin SD
Clin Cancer Res; 2007 Oct; 13(19):5897-902. PubMed ID: 17908985
[TBL] [Abstract][Full Text] [Related]
9. Development of a rapid method to generate multiple oncolytic HSV vectors and their in vivo evaluation using syngeneic mouse tumor models.
Terada K; Wakimoto H; Tyminski E; Chiocca EA; Saeki Y
Gene Ther; 2006 Apr; 13(8):705-14. PubMed ID: 16421599
[TBL] [Abstract][Full Text] [Related]
10. Treatment of cholangiocarcinoma with oncolytic herpes simplex virus combined with external beam radiation therapy.
Jarnagin WR; Zager JS; Hezel M; Stanziale SF; Adusumilli PS; Gonen M; Ebright MI; Culliford A; Gusani NJ; Fong Y
Cancer Gene Ther; 2006 Mar; 13(3):326-34. PubMed ID: 16138120
[TBL] [Abstract][Full Text] [Related]
11. Oncolytic recombinant herpes simplex virus for treatment of orthotopic liver tumors in nude mice.
Chung YS; Miyatake S; Miyamoto A; Miyamoto Y; Dohi T; Tanigawa N
Int J Oncol; 2006 Apr; 28(4):793-8. PubMed ID: 16525626
[TBL] [Abstract][Full Text] [Related]
12. Effective therapy of metastatic ovarian cancer with an oncolytic herpes simplex virus incorporating two membrane fusion mechanisms.
Nakamori M; Fu X; Meng F; Jin A; Tao L; Bast RC; Zhang X
Clin Cancer Res; 2003 Jul; 9(7):2727-33. PubMed ID: 12855653
[TBL] [Abstract][Full Text] [Related]
13. Analysis of factors influencing kinetics of herpes simplex virus transcription utilizing recombinant virus.
Wagner EK; Petroski MD; Pande NT; Lieu PT; Rice M
Methods; 1998 Sep; 16(1):105-16. PubMed ID: 9774520
[TBL] [Abstract][Full Text] [Related]
14. Delivery of herpes simplex virus vectors through liposome formulation.
Fu X; Zhang X
Mol Ther; 2001 Nov; 4(5):447-53. PubMed ID: 11708881
[TBL] [Abstract][Full Text] [Related]
15. An HSV-1 amplicon system for prostate-specific expression of ICP4 to complement oncolytic viral replication for in vitro and in vivo treatment of prostate cancer cells.
Lee CY; Bu LX; Rennie PS; Jia WW
Cancer Gene Ther; 2007 Jul; 14(7):652-60. PubMed ID: 17479106
[TBL] [Abstract][Full Text] [Related]
16. Antitumoral effects of defective herpes simplex virus-mediated transfer of tissue inhibitor of metalloproteinases-2 gene in malignant glioma U87 in vitro: consequences for anti-cancer gene therapy.
Hoshi M; Harada A; Kawase T; Uyemura K; Yazaki T
Cancer Gene Ther; 2000 May; 7(5):799-805. PubMed ID: 10830727
[TBL] [Abstract][Full Text] [Related]
17. Dominant-negative fibroblast growth factor receptor expression enhances antitumoral potency of oncolytic herpes simplex virus in neural tumors.
Liu TC; Zhang T; Fukuhara H; Kuroda T; Todo T; Canron X; Bikfalvi A; Martuza RL; Kurtz A; Rabkin SD
Clin Cancer Res; 2006 Nov; 12(22):6791-9. PubMed ID: 17121900
[TBL] [Abstract][Full Text] [Related]
18. Anti-tumor efficacy of a transcriptional replication-competent adenovirus, Ad-OC-E1a, for osteosarcoma pulmonary metastasis.
Li X; Jung C; Liu YH; Bae KH; Zhang YP; Zhang HJ; Vanderputten D; Jeng MH; Gardner TA; Kao C
J Gene Med; 2006 Jun; 8(6):679-89. PubMed ID: 16570242
[TBL] [Abstract][Full Text] [Related]
19. Targeting cancer by transcriptional control in cancer gene therapy and viral oncolysis.
Dorer DE; Nettelbeck DM
Adv Drug Deliv Rev; 2009 Jul; 61(7-8):554-71. PubMed ID: 19394376
[TBL] [Abstract][Full Text] [Related]
20. Imaging immediate-early and strict-late promoter activity during oncolytic herpes simplex virus type 1 infection and replication in tumors.
Yamamoto S; Deckter LA; Kasai K; Chiocca EA; Saeki Y
Gene Ther; 2006 Dec; 13(24):1731-6. PubMed ID: 16871231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]